Modern treatment of thalassaemia intermedia (Q36848269)

16 August 2017

1 reference

title

Modern treatment of thalassaemia intermedia (English)

1 reference

16 August 2017

Caterina Borgna-Pignatti

series ordinal

1

1 reference

PubMed ID

17565568

16 August 2017

language of work or name

English

0 references

publication date

12 June 2007

1 reference

British Journal of Haematology

16 August 2017

1 reference

16 August 2017

138

1 reference

16 August 2017

3

1 reference

16 August 2017

291-304

1 reference

Pulmonary hypertension in beta-thalassemia

16 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Pseudoxanthoma elasticum-like skin lesions and angioid streaks in beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Cardiac involvement in thalassemia intermedia: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Chronic oxidative stress reduces the respiratory burst response of neutrophils from beta-thalassaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/beta-thalassemia patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Hepatocellular carcinoma in the thalassaemia syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Left ventricular remodelling, and systolic and diastolic function in young adults with beta thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Exploring the role of hepcidin, an antimicrobial and iron regulatory peptide, in increased iron absorption in beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Correction of the sickle cell mutation in embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Hypertransfusion: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Cardiovascular involvement in thalassaemic patients with pseudoxanthoma elasticum-like skin lesions: a long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Long-term hydroxyurea therapy in beta-thalassaemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Hydroxyurea in thalassemia intermedia--a promising therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

The hypercoagulable state in thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Labile plasma iron in iron overload: redox activity and susceptibility to chelation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Asplenic-hyposplenic overwhelming sepsis: postsplenectomy sepsis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with beta-thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Tophaceous gout in a patient with thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Reduced-intensity regimens in allogeneic hematopoietic stem cell transplantation for hemoglobinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Hydroxyurea therapy in thalassemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Anabolic agents for treating postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Effects of N-acetylcysteine on dense cell formation in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Do alpha deletions influence hydroxyurea response in thalassemia intermedia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Butryic acid analogues augment gamma globin gene expression in neonatal erythroid progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Molecular therapies in beta-thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Clinical practice. Postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

New trends in the treatment of beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Oral phosphate binders in the treatment of pseudoxanthoma elasticum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Oxidation resistance of LDL is correlated with vitamin E status in beta-thalassemia intermedia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia intermedia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Cytoprotective effects of the antioxidant phytochemical indicaxanthin in beta-thalassemia red blood cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Infections and thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Pulmonary hypertension in sickle cell disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Low bone mineral density in adolescents with beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Butyrate increases the efficiency of translation of gamma-globin mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Effects of prenatal hydroxyurea-treatment on mouse offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

Correction of sickle cell disease by homologous recombination in embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06654.X

10.1111/J.1365-2141.2007.06654.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17565568